Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
2.
J Geriatr Cardiol ; 20(4): 268-275, 2023 Apr 28.
Article in English | MEDLINE | ID: mdl-37122990

ABSTRACT

OBJECTIVE: To access the efficacy and safety of the double-ProGlide technique for the femoral vein access-site closure in cryoballoon ablation with uninterrupted oral anticoagulants (OAC), and its impact on the electrophysiology laboratory time as well as hospital stay after the procedure in this observational study. METHODS: Patients with atrial fibrillation undergoing cryoballoon ablation with uninterrupted OAC at Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China from May 2019 to May 2021 were enrolled in this study. From October 2020, double-ProGlide technique was consistently used for hemostasis (ProGlide group), and before that conventional manual compression was utilized (manual compression group). The occurrence of vascular and groin complications was accessed during the hospital stay and until the three-month follow-up. RESULTS: A total of 140 participants (69.30% of male, mean age: 59.21 ± 10.29 years) were evaluated, 70 participants being in each group. Immediate hemostasis was achieved in all the patients with ProGlide closure. No major vascular complications were found in the ProGlide group while two major vascular complications were occurred in the manual compression group. The incidence of any groin complication was obviously higher in subjects with manual compression than patients with ProGlide devices (15.71% vs. 2.86%, P = 0.009). In addition, compared with the manual compression group, the ProGlide group was associated with significantly shorter total time in the electrophysiology laboratory [112.0 (93.3-128.8) min vs. 123.5 (107.3-158.3) min, P = 0.006], time from sheath removal until venous site hemostasis [3.8 (3.4-4.2) min vs. 8.0 (7.6-8.5) min, P < 0.001], bed rest time [8.0 (7.6-8.0) h vs. 14.1 (12.0-17.6) h, P < 0.001] and hospital stay after the procedure [13.8 (12.5-17.8) h vs. 38.0 (21.5-41.0) h, P < 0.001]. CONCLUSIONS: Utilization of the double-ProGlide technique for hemostasis after cryoballoon ablation with uninterrupted OAC is feasible and safe, which has the clinical benefit in reducing the total electrophysiology laboratory time and the hospital stay length after the procedure.

3.
Curr Med Sci ; 43(3): 560-571, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37142816

ABSTRACT

OBJECTIVE: Cisplatin (CDDP)-based chemotherapy is a first-line, drug regimen for muscle-invasive bladder cancer (BC) and metastatic bladder cancer. Clinically, resistance to CDDP restricts the clinical benefit of some bladder cancer patients. AT-rich interaction domain 1A (ARID1A) gene mutation occurs frequently in bladder cancer; however, the role of CDDP sensitivity in BC has not been studied. METHODS: We established ARID1A knockout BC cell lines using CRISPR/Cas9 technology. IC50 determination, flow cytometry analysis of apoptosis, and tumor xenograft assays were performed to verify changes in the CDDP sensitivity of BC cells losing ARID1A. qRT-PCR, Western blotting, RNA interference, bioinformatic analysis, and ChIP-qPCR analysis were performed to further explore the potential mechanism of ARID1A inactivation in CDDP sensitivity in BC. RESULTS: It was found that ARID1A inactivation was associated with CDDP resistance in BC cells. Mechanically, loss of ARID1A promoted the expression of eukaryotic translation initiation factor 4A3 (EIF4A3) through epigenetic regulation. Increased expression of EIF4A3 promoted the expression of hsa_circ_0008399 (circ0008399), a novel circular RNA (circRNA) identified in our previous study, which, to some extent, showed that ARID1A deletion caused CDDP resistance through the inhibitory effect of circ0008399 on the apoptosis of BC cells. Importantly, EIF4A3-IN-2 specifically inhibited the activity of EIF4A3 to reduce circ0008399 production and restored the sensitivity of ARID1A inactivated BC cells to CDDP. CONCLUSION: Our research deepens the understanding of the mechanisms of CDDP resistance in BC and elucidates a potential strategy to improve the efficacy of CDDP in BC patients with ARID1A deletion through combination therapy targeting EIF4A3.


Subject(s)
Cisplatin , Drug Resistance, Neoplasm , Urinary Bladder Neoplasms , Humans , Cell Line, Tumor , Cisplatin/pharmacology , Cisplatin/therapeutic use , DEAD-box RNA Helicases/genetics , DEAD-box RNA Helicases/metabolism , DEAD-box RNA Helicases/pharmacology , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Drug Resistance, Neoplasm/genetics , Epigenesis, Genetic , Eukaryotic Initiation Factor-4A/genetics , Eukaryotic Initiation Factor-4A/metabolism , Eukaryotic Initiation Factor-4A/pharmacology , Transcription Factors/genetics , Transcription Factors/metabolism , Transcription Factors/pharmacology , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/genetics
4.
Inorg Chem ; 61(1): 47-51, 2022 Jan 10.
Article in English | MEDLINE | ID: mdl-34935390

ABSTRACT

Under solvothermal conditions, a three-dimensional mononuclear crystal AQNU-1, {[Co(H2L)(DPD)(H2O)2]·2DMA}n (H2L = 5-(bis(4-carboxybenzyl)amino)isophthalic acid, DPD = 4,4'-(2,5-diethoxy-1,4-phenylene)dipyridine) has been synthesized. The transformations of AQNU-1 to binuclear {[Co2(L)(DPD)1.5(H2O)3]·DMA·H2O}n (AQNU-2) and pentanuclear {[Co5(L)2(DPD)2(OH)2]·2H2O}n (AQNU-3) were realized by double stimulation of temperature and solvent, which were accomplished by single-crystal to single-crystal (SC-SC) reaction.

5.
Sci Total Environ ; 801: 149689, 2021 Dec 20.
Article in English | MEDLINE | ID: mdl-34425446

ABSTRACT

Existing studies on vertical profiling of black carbon (BC) and ozone (O3) were mainly conducted in the rural areas, leading to limited knowledge of their vertical distributions in the urban area. To fill this knowledge gap, vertical profiling (0-500 m and 0-900 m, AGL) of BC and O3 was conducted in a highly urbanized area of Shenzhen in subtropical South China using a multicopter unmanned aerial vehicle (UAV) platform. In total 32 flights were conducted from the 10th to 15th, December 2017 (winter campaign) and 42 flights from the 19th to 28th, August 2018 (summer campaign) with 4 time slots per day, including morning, afternoon, evening, and midnight. In general, equivalent BC (eBC) concentration decreased as the height increased with an overall slope of -0.13 µg m-3 per 100 m in the winter campaign and -0.08 µg m-3 per 100 m in the summer campaign. On the contrary, an increase of O3 level with altitude was observed (7.8 ppb per 100 m). Absorption Ångström exponent (AAE) exhibits a slightly increasing trend with height. Seasonality of eBC vertical profiles was observed in morning, afternoon and midnight flights, but not for evening flights. The analysis showed the shape of vertical profiles of eBC and O3 can be affected by planetary boundary layer height (PBLH) and air mass origin. Calculated heating rates due to BC show distinct seasonal variability for morning but not for afternoon, because of the counteracting effects by solar irradiance in the subtropical afternoon and eBC concentration in urban South China influenced by the monsoon climate.


Subject(s)
Air Pollutants , Ozone , Air Pollutants/analysis , Carbon/analysis , China , Environmental Monitoring , Ozone/analysis , Seasons
6.
Curr Med Sci ; 39(1): 94-98, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30868497

ABSTRACT

Using anesthetic gel may not sufficiently exclude pain perception during and after cystoscopy in male patients. To evaluate the analgesic efficacy and safety of intramuscular parecoxib (40 mg) for outpatient-based rigid cystoscopy, we performed a prospective, randomized and controlled study. Consecutive male patients requiring diagnostic cystoscopy in our hospital were divided into group A (1% tetracaine gel, n=50) and group B (parecoxib, n=51) at random. Patients received intramuscular injections of either 2 mL sterile saline in group A or 40 mg parecoxib in group B 30 min before the procedure. Tetracaine gel was injected into the urethra 3 min before the procedure in group A, with patients receiving plain lubricant gel in group B at the same time. Cystoscopy-associated pain levels were evaluated using the Visual Analog Score (VAS) during the procedure. Post-procedure urethral pain and complications were recorded and analyzed. The results showed that male patients experienced significantly less pain in group B than in group A (2.70±1.36 vs. 3.56±1.74, P=0.008). The percentage of patients with dysuria pain was not significantly different between the two groups. In addition, 24 h after cystoscopy, the patients with no previous experience of cystoscopy were more likely to declare urethral pain (59.2% vs. 33.3%, P=0.012, relative risk=1.78). No difference was observed in analgesic-related complications between the two groups. We conclude that intramuscular injection of 40 mg parecoxib may improve comfort for male patients undergoing rigid cystoscopy.


Subject(s)
Cyclooxygenase 2 Inhibitors/administration & dosage , Cystoscopy/adverse effects , Isoxazoles/administration & dosage , Pain/drug therapy , Tetracaine/administration & dosage , Ambulatory Care Facilities , Cyclooxygenase 2 Inhibitors/therapeutic use , Cystoscopy/instrumentation , Double-Blind Method , Humans , Injections, Intramuscular , Isoxazoles/therapeutic use , Male , Middle Aged , Pain/etiology , Pain Management , Pain Measurement , Prospective Studies , Tetracaine/therapeutic use , Treatment Outcome
7.
Clinics (Sao Paulo) ; 68(5): 665-73, 2013 May.
Article in English | MEDLINE | ID: mdl-23778412

ABSTRACT

OBJECTIVE: We aimed to assess the chemotactic response of endothelial progenitor cells to angiotensin-converting enzyme inhibitors in T2DM patients after acute myocardial infarction, as well as the associated prognosis. METHODS: Sixty-eight T2DM patients with acute myocardial infarction were randomized to either receive or not receive daily oral perindopril 4 mg, and 36 non-diabetic patients with acute myocardial infarction were enrolled as controls. The numbers of circulating CD45-/low+CD34+CD133+KDR+ endothelial progenitor cells, as well as the stromal cell-derived factor-α and high-sensitivity C reactive protein levels, were measured before acute percutaneous coronary intervention and on days 1, 3, 5, 7, 14, and 28 after percutaneous coronary intervention. Patients were followed up for 6 months. Chinese Clinical Trial Registry: ChiCTR-TRC-12002599. RESULTS: T2DM patients had lower circulating endothelial progenitor cell counts, decreased plasma vascular endothelial growth factor and α levels, and higher plasma high-sensitivity C reactive protein levels compared with non-diabetic controls. After receiving perindopril, the number of circulating endothelial progenitor cells increased from day 3 to 7, as did the plasma levels of vascular endothelial growth factor and stromal cell-derived factor-α, compared with the levels in T2DM controls. Plasma high-sensitivity C reactive protein levels in the treated group decreased to the same levels as those in non-diabetic controls. Furthermore, compared with T2DM controls, the perindopril-treated T2DM patients had lower cardiovascular mortality and occurrence of heart failure symptoms (p<0.05) and better left ventricle function (p<0.01). CONCLUSIONS: The use of angiotensin-converting enzyme inhibitors represents a novel approach for improving cardiovascular repair after acute myocardial infarction in T2DM patients.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Diabetes Mellitus, Type 2/complications , Endothelial Cells/drug effects , Hematopoietic Stem Cell Mobilization , Myocardial Infarction/drug therapy , Perindopril/therapeutic use , Stem Cells/drug effects , Aged , C-Reactive Protein/analysis , Chemokine CXCL12/blood , Diabetes Mellitus, Type 2/blood , Endothelial Cells/cytology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Myocardial Infarction/blood , Myocardial Infarction/complications , Prognosis , Prospective Studies , Stem Cells/cytology , Vascular Endothelial Growth Factor A/blood
8.
Clinics ; 68(5): 665-673, maio 2013. tab, graf
Article in English | LILACS | ID: lil-675755

ABSTRACT

OBJECTIVE: We aimed to assess the chemotactic response of endothelial progenitor cells to angiotensin-converting enzyme inhibitors in T2DM patients after acute myocardial infarction, as well as the associated prognosis. METHODS: Sixty-eight T2DM patients with acute myocardial infarction were randomized to either receive or not receive daily oral perindopril 4 mg, and 36 non-diabetic patients with acute myocardial infarction were enrolled as controls. The numbers of circulating CD45−/low+CD34+CD133+KDR+ endothelial progenitor cells, as well as the stromal cell-derived factor-α and high-sensitivity C reactive protein levels, were measured before acute percutaneous coronary intervention and on days 1, 3, 5, 7, 14, and 28 after percutaneous coronary intervention. Patients were followed up for 6 months. Chinese Clinical Trial Registry: ChiCTR-TRC-12002599. RESULTS: T2DM patients had lower circulating endothelial progenitor cell counts, decreased plasma vascular endothelial growth factor and α levels, and higher plasma high-sensitivity C reactive protein levels compared with non-diabetic controls. After receiving perindopril, the number of circulating endothelial progenitor cells increased from day 3 to 7, as did the plasma levels of vascular endothelial growth factor and stromal cell-derived factor-α, compared with the levels in T2DM controls. Plasma high-sensitivity C reactive protein levels in the treated group decreased to the same levels as those in non-diabetic controls. Furthermore, compared with T2DM controls, the perindopril-treated T2DM patients had lower cardiovascular mortality and occurrence of heart failure symptoms (p<0.05) and better left ventricle function (p<0.01). CONCLUSIONS: The use of angiotensin-converting enzyme inhibitors represents a novel approach for improving cardiovascular repair after acute myocardial infarction in T2DM patients. .


Subject(s)
Aged , Female , Humans , Male , Middle Aged , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , /complications , Endothelial Cells/drug effects , Hematopoietic Stem Cell Mobilization , Myocardial Infarction/drug therapy , Perindopril/therapeutic use , Stem Cells/drug effects , C-Reactive Protein/analysis , /blood , /blood , Endothelial Cells/cytology , Follow-Up Studies , Myocardial Infarction/blood , Myocardial Infarction/complications , Prognosis , Prospective Studies , Stem Cells/cytology , Vascular Endothelial Growth Factor A/blood
9.
Ying Yong Sheng Tai Xue Bao ; 19(4): 911-4, 2008 Apr.
Article in Chinese | MEDLINE | ID: mdl-18593057

ABSTRACT

The quantitative changes of anti-cancer ingredients such as taxol, cephalomannine, baccatin III and 10-deacetylbaccatin III in the branches and leaves of Taxus chinensis var. mairei during one growth season were measured by HPLC. The results showed that the contents of these anticancer ingredients had an obvious change from April when the new branches began to germinate to November when the branches basically stopped growing. The contents of taxol and cephalomannine in the branches and leaves of T. chinensis had the same change pattern, with the peaks appeared in May, and those of Baccatin III and 10-deacetylbaccatin III had the same change trend, with the highest values appeared in September and April, respectively. There was a significant positive correlation between the contents of taxol and cephalomannine (P <0.05), and a negative correlation between the contents of cephalomannine and 10-deacetylbaccatin III (P <0.05).


Subject(s)
Antineoplastic Agents, Phytogenic/analysis , Plant Leaves/chemistry , Seasons , Taxus/chemistry , Alkaloids/analysis , Chromatography, High Pressure Liquid , Paclitaxel/analysis , Plant Leaves/growth & development , Taxoids/analysis , Taxus/growth & development
10.
Zhonghua Nan Ke Xue ; 14(1): 7-10, 2008 Jan.
Article in Chinese | MEDLINE | ID: mdl-18297802

ABSTRACT

OBJECTIVE: To set up a stable primary culture system of Leydig cells with higher purity. METHODS: We separated Leydig cells from other testicular cells, such as Sertoli and germ cells, by enzymatic digestion in combination with Percoll density gradient centrifugation and identified Leydig cells by 3beta-HSD staining. RESULTS: The purity achieved by this method was above 95% and the total number of Leydig cells obtained from one testicle was about 1 x 10(6). The cytoplasm of Leydig cells was stained in deep blue by 3beta-HSD staining, and these cells possessed testosterone-secreting capability. CONCLUSION: Leydig cells can be separated by enzymatic digestion combined with Percoll density gradient centrifugation, and 3beta-HSD staining to identify Leydig cells is simple and feasible with high purity.


Subject(s)
Cell Separation/methods , Leydig Cells/cytology , 3-Hydroxysteroid Dehydrogenases/metabolism , Animals , Cell Culture Techniques , Cells, Cultured , Centrifugation, Density Gradient/methods , Histocytochemistry , Leydig Cells/enzymology , Leydig Cells/physiology , Male , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...